KSHN 001034
Alternative Names: KSHN-001034Latest Information Update: 13 Oct 2023
At a glance
- Originator Kashiv BioSciences
- Class Antineoplastics; Estradiol congeners; Estrenes; Fluorinated hydrocarbons; Sulfoxides
- Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Breast cancer
Most Recent Events
- 01 Oct 2023 Kashiv BioSciences completes a phase I trial in Breast cancer (In volunteers) in Jordan (IM) (NCT06074757)
- 14 Apr 2023 Pharmacodynamic and pharmacokinetics data from preclinical trial in Breast cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 01 Mar 2023 Phase-I clinical trials in Breast cancer (In volunteers) in Jordan (IM) (NCT06074757)